ACTU

MKT CAP:$69M

Actuate Therapeutics Inc

Market Cap

$69M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$2.40-$3.63 (-60.12%)

Apr 22, 2026

Company Details

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor...

CEO

Daniel Schmitt

IPO Date

Aug 13, 2024

Website

actuatetherapeutics.com

Key Metrics TTM

Revenue

$0

— YoY

Net Income

-$22M

EPS (Diluted)

-$1.07

Free Cash Flow

-$19M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

FY 2025

Mar 26, 2026

$0EPS -$1.06

Q4 2025

Mar 26, 2026

$0EPS -$0.20

Q3 2025

Nov 13, 2025

$0EPS -$0.25

Q2 2025

Aug 14, 2025

$0EPS -$0.30

Q1 2025

May 15, 2025

$0EPS -$0.32

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 23	$0	$0	-$5M
Q2 23	$0	$0	-$6M
Q3 23	$0	$0	-$6M
Q4 23	$0	$0	-$8M
Q1 24	$0	$0	-$8M
Q2 24	$0	$0	-$5M
Q3 24	$0	$0	-$5M
Q4 24	$0	$0	-$7M
Q1 25	$0	$0	-$6M
Q2 25	$0	$0	-$6M
Q3 25	$0	$0	-$5M
Q4 25	$0	$0	-$5M

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 23	-$5M	-$5M
Q2 23	-$5M	-$5M
Q3 23	-$6M	-$6M
Q4 23	-$6M	-$6M
Q1 24	-$5M	-$5M
Q2 24	-$3M	-$3M
Q3 24	-$9M	-$9M
Q4 24	-$5M	-$5M
Q1 25	-$5M	-$5M
Q2 25	-$4M	-$4M
Q3 25	-$7M	-$7M
Q4 25	-$4M	-$4M

Capital Expenditures

Quarter	CapEx
Q1 23	$1
Q2 23	$0
Q3 23	$0
Q4 23	$0
Q1 24	$0
Q2 24	$0
Q3 24	$0
Q4 24	$5
Q1 25	$0
Q2 25	$3
Q3 25	$0
Q4 25	$3

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 24	—	+46.7%
Q2 24	—	-2.7%
Q3 24	—	-16.7%
Q4 24	—	-13.9%
Q1 25	—	-18.1%
Q2 25	—	+9.8%
Q3 25	—	+1.5%
Q4 25	—	-28.5%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 23	$0	—
Q2 23	$73.1K	—
Q3 23	$155.2K	—
Q4 23	$122.0K	—
Q1 24	$148.2K	—
Q2 24	$90.0K	—
Q3 24	$566.0K	—
Q4 24	$1M	—
Q1 25	$1M	—
Q2 25	$0	—
Q3 25	$2M	—
Q4 25	$2M	—

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q1 23	$5M	$774.8K	—
Q2 23	$5M	$807.2K	—
Q3 23	$6M	$714.2K	—
Q4 23	$7M	$969.4K	—
Q1 24	$7M	$912.8K	—
Q2 24	$4M	$1M	—
Q3 24	$4M	$2M	—
Q4 24	$4M	$3M	—
Q1 25	$3M	$3M	—
Q2 25	$3M	$3M	—
Q3 25	$2M	$3M	—
Q4 25	$2M	—	$3M

War Chest

Quarter	Cash	Short-term Investments	Total
Q4 23	$3M	$0	$3M
Q1 24	$2M	$0	$2M
Q2 24	$351.7K	$0	$351.7K
Q3 24	$14M	$0	$14M
Q4 24	$9M	$0	$9M
Q1 25	$4M	$0	$4M
Q2 25	$6M	$0	$6M
Q3 25	$17M	$0	$17M
Q4 25	$13M	$0	$13M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 23	13M	—	—
Q2 23	14M	+6.2%	—
Q3 23	15M	+8.9%	—
Q4 23	15M	-1.5%	—
Q1 24	15M	+1.5%	+15.6%
Q2 24	20M	+26.1%	+37.3%
Q3 24	20M	-0.1%	+26.0%
Q4 24	20M	0.0%	+27.9%
Q1 25	19M	-0.1%	+25.9%
Q2 25	20M	+0.8%	+0.6%
Q3 25	21M	+8.9%	+9.6%
Q4 25	23M	+8.6%	+19.1%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 23	—	—
Q2 23	—	—
Q3 23	—	—
Q4 23	—	—
Q1 24	—	—
Q2 24	—	—
Q3 24	—	—
Q4 24	$0	200K
Q1 25	$0	200K
Q2 25	$0	200K
Q3 25	$0	200K
Q4 25	$0	200K

Revenue / Employee